Analysis of differentially expressed proteins in cancerous and normal colonic tissues

Lay-Harn Gam, Chuan-Herng Leow, Che Nin Man, Boon-Hui Gooi, Manjit Singh

Abstract

AIM: To identify and analyze the differentially expressed proteins in normal and cancerous tissues of four patients suffering from colon cancer.

METHODS: Colon tissues (normal and cancerous) were homogenized and the proteins were extracted using three protein extraction buffers. The extraction buffers were used in an orderly sequence of increasing extraction strength for proteins with hydrophobic properties. The protein extracts were separated using the SDS-PAGE method and the images were captured and analyzed using Quantity One software. The target protein bands were subjected to in-gel digestion with trypsin and finally analyzed using an ESI-ion trap mass spectrometer.

RESULTS: A total of 50 differentially expressed proteins in colonic cancerous and normal tissues were identified.

CONCLUSION: Many of the identified proteins have been reported to be involved in the progression of similar or other types of cancers. However, some of the identified proteins have not been reported before. In addition, a number of hypothetical proteins were also identified.

© 2006 The WJG Press. All rights reserved.

Key words: Colon cancer; Tissue specimens; Sequential protein extraction; Proteomics

INTRODUCTION

Colorectal cancer is a worldwide public health concern and also a frequent cause of mortality and morbidity in developed, developing and industrialized countries[1]. The incidence of colon cancer increases exponentially with age. Environmental factors and host immunological characteristics could contribute to initiation and progression of the disease[2]. Colorectal cancer is among the best characterized cancers with regard to the genetic progression of the disease[3].

The ability to obtain maps of the protein content of cells provides a basis for comparison of the protein expression in normal and cancer cells. This capability becomes especially important for mapping the changes that occur during cancer progression. In the transformation process, changes in protein expression may result in expression of proteins at elevated or reduced levels[4]. When a cell transforms from normal to malignant, changes in protein expression ultimately are reflected in the phenotype of the cell. It is also important to map the differences between different stages of cancer and between different cancer samples at the same stage of progression in order to understand the pathways involved in these processes. Ultimately, identification of important proteins involved in the transformation process may lead to the identification of early markers for detection of specific types of cancers and their treatments[5].

In the present study, proteins from normal and cancerous colon tissues were extracted in three separate fractions. The mapping of a protein profile in each fraction was carried out individually. This approach eases the comparison of protein expression in normal and cancerous tissue as it reduces the total proteins present in each fraction. Using this method, we believe that proteins from different compartments of the cells were extracted in sequential order, where the aqueous soluble proteins were first extracted followed by non-aqueous soluble proteins consisting of proteins with moderate to extreme hydrophobicity. The proteins analyzed in this study were extracted from human tissue specimens (both cancerous and normal). In proteomics study, analysis of cancerous
tissue has advantages over analysis in established cancer cell lines, as the latter may not represent the actual expression of proteins.

**MATERIALS AND METHODS**

**Tissue specimen collection**

Normal and cancerous colonic tissues were collected from patients with colon cancer. The specimens were provided by Hospital Pulau Pinang. Normal tissue was taken from the mucosal layer of the normal colon adjacent to the tumor tissue. Both the normal and cancerous tissues were confirmed by hospital pathologists. Ulceration or infected colon cancers were exclusion criteria for the study. The tissues were collected after informed consent had been obtained from the patients. The patients had different grades of colorectal cancer as shown in Table 1. The tissues were cut into similar sizes, weighed and immediately stored at -70°C until analyzed.

Well-differentiated adenocarcinoma refers to the less aggressive type of cancer where the cancerous tissues more closely resemble the normal tissue under histopathological examination, whereas moderately differentiated adenocarcinoma refers to moderately aggressive cancer cells.

**Tissue lysis and sequential extractions**

The tissues were defatted and an equal weight of tissues (normal and cancerous) was determined and subjected to analysis. The deep-frozen colon tissue specimens were disrupted by grinding in a liquid nitrogen-cooled mortar until the specimens became powder-form. The powder form-like tissues were divided into aliquots in separate eppendorf tubes. Sequential extraction of protein using three protein extraction buffers was carried out. These extraction buffers were prepared according to Molloy et al. with modifications. The extraction procedures are described in the following sections.

**Tris extraction buffer**

The constituent of Extraction Buffer 1 (S1 buffer) is 40 mM Urea, 2 mol/L Thiourea, 50 mmol/L DTT, 20 g/L CHAPS, 20 mL/L Triton, 2 mL/L Carrier ampholytes (pH 3-10), 40 mmol/L Tris and 2 mg/L Bromophenol Blue. The recovered pellet from S2 extraction was washed twice with S2 buffer, it was then vortexed, centrifuged and the supernatant was discarded. After washing, 1000 μL of S3 buffer was added to the pellet. The mixture was vortexed for 30 s and then centrifuged at 20°C with the speed of 12000 r/min for 8 min. The supernatant was collected in aliquots (50 μL) and kept at -70°C. The pellet was thoroughly washed with S1 buffer before being subjected to the second step in the sequential extraction.

**Solution two extraction buffer**

The extraction Buffer 2 (S2 buffer) contained 8 mol/L Urea, 50 mmol/L DTT, 40 g/L CHAPS, 2 mL/L Carrier ampholytes (pH 3-10) and 2 mg/L Bromophenol Blue. The recovered pellet was washed twice again with the T1 solution, and was then vortexed, centrifuged and the supernatant was discarded. After washing, a volume of 1000 μL S2 solution was added to the pellet. The mixture was then vortex for 30 s and then centrifuged at 20°C with the speed of 12000 r/min for 8 min. The supernatant was collected in aliquots (50 μL) and kept at -70°C. The pellet was thoroughly washed with the same extraction buffer before being subjected to the third step in the sequential extraction.

**Solution three extraction Buffer**

The extraction Buffer 3 (S3 buffer) contained 5 M Urea, 2 mol/L Thiourea, 50 mmol/L DTT, 20 g/L CHAPS, 20 mL/L Triton, 2 mL/L Carrier ampholytes (pH 3-10), 40 mmol/L Tris and 2 mg/L Bromophenol Blue. The recovered pellet from S2 extraction was washed twice with S2 buffer, it was then vortexed, centrifuged and the supernatant was discarded. After washing, 1000 μL of S3 buffer was added to the pellet. The mixture was vortexed for 30 s and then centrifuged at 20°C with the speed of 12000 r/min for 8 min. The supernatant was collected in aliquots (50 μL) and kept at -70°C. The pellet was then discarded.

**Sample preparation and electrophoresis**

The preparation of protein samples for SDS-PAGE separation was carried out by adding 200 mL/L of sample buffer (0.5 mol/L Tris-HCl, 100 mL/L glycerol, 20 mg/L SDS, 100 mg/L Coomassie blue) to each fraction (5 μL) and vortexed for 30 s. The samples (normal and cancerous) and the protein molecular weights markers were then loaded into individual wells of SDS-polyacrylamide gel using a syringe. Electrophoresis was performed using a vertical electrophoresis slab gel apparatus at a constant voltage of 200 volts throughout the electrophoresis process. Electrophoresis was terminated when the dye front was 2 to 3 mm away from the bottom edge of the gel for both experiments. The gel was stained with Coomassie blue.

**In-gel digestion**

The SDS-Polyacrylamide gel was washed thoroughly in 100 mmol/L NH₂HCO₃ and the differentially expressed protein bands from either normal or cancerous colonic tissues were then excised from the gel. In-gel digestion was performed using trypsin according to Gam and Aishah with slight modification. The gel pieces were first excised and shrunk by dehydration in acetoniitrile. The solvent was then discarded and the gel pieces were dried in a vacuum centrifuge. A volume of 10 mmol/L dithioretil (DTT) in 100 mmol/L NH₂HCO₃ that was sufficient to cover the gel pieces was added and the protein was reduced.

**Table 1 Clinical and pathological data of patient tissue specimens**

| Patient # | Age | Gender | Race | Cancer stage | Cancer grade |
|-----------|-----|--------|------|--------------|--------------|
| MMN       | 77  | Female | Malay| Stage IV     | Well differentiated adenocarcinoma |
| LKH       | 66  | Male   | Chinese| Stage II    | Moderately differentiated adenocarcinoma |
| CCH       | 55  | Male   | Chinese| Stage IV    | Moderately differentiated adenocarcinoma |
| NSC       | 55  | Female | Chinese| Stage III   | Moderately differentiated adenocarcinoma |
for 1 h at 56°C. After cooling to room temperature, the DTT solution was replaced with the same volume of 55 mmol/L iodoacetic acid in 100 mmol/L NH₄HCO₃. After 45 min incubation at ambient temperature in the dark with occasional vortexing, the gel pieces were washed with 50-100 μL of 100 mmol/L NH₄HCO₃ for 10 min, dehydrated with acetonitrile, rehydrated in 100 mM NH₄HCO₃ and dehydrated in the same volume of acetonitrile. The liquid phase was removed and the gel pieces were dried in a vacuum centrifuge. The gel pieces were swollen in digestion buffer containing 50 mmol/L NH₄HCO₃, 5 mmol/L CaCl₂, and 12.5 ng/μL of trypsin in an ice-cold bath. After 45 min, the supernatant was removed and replaced with 10 μL of the same buffer but without trypsin to keep the gel pieces wet during enzymatic cleavage at 37°C overnight. Peptides were extracted from the gel matrix by adding 15 μL of 20 mmol/L NH₄HCO₃, vortexed and incubated at room temperature for 10 min and the supernatant was recovered after a brief spin. This was followed by adding (1 to 2 times the volume of gel pieces) 50 mL/L formic acid in acetonitrile:water mixture (70:30), vortex and incubated for 20 min at room temperature. It was then spun down and the supernatant was recovered. These steps were repeated 3 times. Pooled extracts were dried in a vacuum centrifuge and stored at -70°C. Each of the pooled extracts (peptides) was added with 30 μL of deionized water. Then, they were centrifuged at 500 r/min for 5 min at 15°C. The extracts were then subjected to LC/MS/MS analysis.

**Mass spectrometric analysis**

A volume of 5 μL of the sample was injected into a RPLC-column (C18 300 A, 5 μm, 1 mm × 150 mm) connected to a Hewlett Packard HPLC. A capillary pump was used to pump the mobile phase at 20 μL/min flow rate, the linear gradient used was 5% B to 95% B in 65 min. Mobile phase A was 500 μL/L formic acid in deionized water and B was 500 μL/L formic acid in ACN. The HPLC was interfaced to an ion trap mass spectrometer. The dry gas temperature was 300°C, dry gas flow rate was of 8.0 L/min, nebulizer pressure of 30.0 psi. The above parameters were used subsequently for acquiring MS data. The peptides were ionized using electrospray soft ionization technique (ESI).

The experimental method was made up of one experimental protocol consisting of 2 scan events. The first scan event was a full scan MS and the second was the data dependent MS/MS scan which is dependent on the results of the first scan event. The most intense ion in a MS scan will be automatically isolated and excited to MS/MS scan. The parameters set for data dependent scan (MS/MS scan) were default collision energy (voltage) = 1.15 V, charge state = 2, minimum threshold = 3000 counts, and the isolation width = 2 m/z.

**Mascot protein identification**

The protein was identified using Mascot Protein Database Search engine. The Peptide Mass Tolerance was set as ±2 u and ±0.8 u was set for the Fragment Mass Tolerance. Only 1 missed cleavage was allowed. This software is available at www.matrix-science.com. Matches were computed using a probability-based Mowse score defined as -10 × log (P), where P is the probability that the observed match was a random event.

**RESULTS**

Figure 1 shows the protein profiles of protein extracted using S1 buffer from normal and cancerous colon tissues of four different patients. Figure 2 shows the consistent protein bands found in the normal and the cancer tissues of the figure.
Diagram 2 represents the consistent protein bands that were expressed in the tissues analyzed. For the cancerous tissues, the protein bands at 76 ku, 38 ku, 32 ku and 25 ku were consistently expressed in all the cancerous tissues analyzed while protein bands at 65 ku, 18 ku and 12 ku were only found in the tissues of three of the four patients. For the normal tissues, the bands at 180 ku, 65 ku, 38 ku, 32 ku and 25 ku were found in the tissues of all four patients while only one band at 12 ku was detected in the tissues of three patients. Most of the proteins extracted from cancerous tissues using S2 buffer were found at the low molecular weight region, in the range of 35 ku to 10 ku. In contrast, relatively few protein bands from normal tissues were detected in this region and those that were detected were present at low protein intensity.

Figure 3 shows the protein profiles of proteins extracted using S3 buffer from normal and cancer colon tissues of the four patients. Diagram 3 represents the consistent protein bands expressed in the four tissues analyzed. Protein bands at 38 ku, 27 ku, 23 ku 20 ku and 17 ku from cancerous tissues were found in all four patients whereas only the band at 65 ku was found in three of the four patients. Normal tissues of the corresponding patients displayed bands at 38 ku, 27 ku and 20 ku whereas tissues from three patients were found to express consistent bands at 150 ku, 100 ku, 65 ku, 46 ku and 35 ku. The protein band at 65 ku was detected at the highest intensity compared to the other bands and it was uniquely expressed in all the patients except for patient #MMN, which was the only patient diagnosed with well differentiated adenocarcinoma cancer. Thus, its expression is probably related to the cancer grade. Nevertheless, this may just be an ambiguous assumption as only one patient with well differentiated cancer grade was analyzed. When comparing the protein profiles of protein extracted from tissues using S3 buffer, it is obvious that the expression of

Table 2  Up-regulated, down-regulated proteins extracted in S1, S2, S3 buffers from colon tissues

| SWISS-PROT accession number | Down-regulated proteins (Normal tissues) | SWISS-PROT accession number | Up-regulated proteins (Cancer tissues) |
|-----------------------------|----------------------------------------|-----------------------------|----------------------------------------|
| PI22718                     | Actin, gamma-enteric smooth muscle     | P04262                     | Type II, keratin subunit protein       |
| PI7661                      | Desmin                                 | P33900                     | Keratin 20                             |
| P00870                      | Vimentin                               | P33908                     | Keratin, 67k type II epidermal         |
| Q9DFD20                     | Hypothetical protein                   | P13647                     | Keratin k5                             |
| Q7Z5W1                      | Hypothetical protein                   | Q86146                     | Keratin 6 ins 3                        |
| CAD19027                    | Hypothetical protein                   | P04264*                    | Keratin 7, type II cytoskeletal        |
| BAC97457                    | Hypothetical protein                   | P33557                     | Cytoskeletal 9                         |
| CAC08866                    | Hypothetical protein                   | P04264                     | Keratin, type II cytoskeletal 1        |
| CAC08835                    | Hypothetical protein                   | P33557                     | Keratin 9, type I, cytoskeletal        |
| Q8WTU6                      | Transgelin                             | P08779                     | Keratin 1, type I, cytoskeleton 16     |
| Q19995                      | Transgelin                             | P48669                     | Keratin, type II, cytoskeletal 6F      |
| Q91706                      | Skeletal muscle beta-tropomyosin       | P02538                     | Keratin 6A, type II                    |
| PI2277                      | Creatine kinase                        | P19013                     | Keratin, type II, cytoskeletal 4       |
| P00915                      | Actin-gamma                            | P08729                     | Keratin, type II, cytoskeletal 7       |
| Q96QE3                      | ATP[GTP]-binding protein               | P12035                     | Keratin, type II, cytoskeletal 3       |
| P07583                      |                                      | P13645                     | Keratin, type I, cytoskeleton 18       |
| Q8NF17                      | Hypothetical protein                   | Q88147                     | Hypothetical protein                   |
| CAE9930                    | Hypothetical protein                   | P02675                     | Fibrinogen beta chain                  |
| P00915                      | Carbonate dehydratase EC 4.2.1.1       | Q87149                     | Kinesin-like protein 2                 |
| Q96143                      | ACTGI protein                          | P60174                     | Triosephosphate isomerase EC 5.3.1.1   |
| Q13733                      | Sodium/potassium-transporting ATPase alpha-4 chain EC 3.6.3.9 |

Figure 3  Proteins profiles of normal and cancer colon tissues from four different patients. The proteins were extracted using S3 buffer. N: Normal colon tissues; C: Cancer colon tissues; M: Marker; Lanes 1 and 2: MMN samples; Lanes 3 and 4: LKH samples; Lanes 5 and 6: CCH samples and Lanes 7 and 8: NSC samples. Diagram 3 shows the consistent protein bands found in the normal and the cancer tissues of the figure.
low molecular weight proteins (below 37 ku) in cancerous tissues was greater than that of the normal tissues.

Table 2 shows the list of proteins detected, with a total of 15 and 24 down-regulated and up-regulated proteins identified from normal and cancerous tissues, respectively. Table 3 shows the unique proteins that were identified form normal and cancerous tissues.

**DISCUSSION**

The sequential protein extraction technique consists of three types of protein extraction buffers, namely the S1 buffer, S2 buffer and S3 buffer. The S1 buffer is used mainly to extract aqueous soluble proteins, such as cytosolic proteins and nuclear proteins while the S2 and S3 buffers were used to extract proteins with intermediate to extreme hydrophobicity. The constituent of S2, which is made up of chaotropic agents and other reagents may disturb rugged protein-protein interaction found among structural, cytoskeletal proteins and aggregating proteins. However, the combination of urea and thioureas in S3 was used to enhance the solubility of membrane proteins. The extraction buffers were always used in the orderly sequence of S1 followed by S2 and then S3. The use of sequential protein extraction buffers was first suggested by Molloy et al. for separation of protein mixtures using 2D-gel electrophoresis. However, in our present study, the extracted proteins were separated using the SDS-PAGE technique, whereby direct comparison of protein profiles from tissues of four different patients was carried out.

In general, use of sequential extraction buffers is beneficial to this study because proteins were extracted according to their increasing hydrophobic strength, which may imply that proteins from different cellular compartments were extracted in different fractions. This method not only allows the analysis of proteins according to their localization in the cells but also reduces the number of proteins extracted in each fraction, which provides better resolution of proteins and their visualization in SDS-PAGE.

The protein profiles of the proteins extracted using the S1 and S2 buffers are significantly different, however the protein profiles of proteins extracted using S2 and S3 showed only slight differences. The significant variation between the protein profiles of S1 and S2 can be explained by the vast difference in the property of the proteins extracted, where S1 buffer extracts proteins only solubilize in aqueous solution while S2 buffer extracts the non-aqueous soluble proteins. The protein profiles displayed by proteins extracted using S2 and S3 also showed a certain degree of variation as S3 buffer was used to enhance the solubility of more stringent proteins from the tissue.

The differentially expressed proteins in each of the gels were then subjected to further analysis and the identity of each protein was analyzed using LC/MS/MS. Proteins were identified using the Mascot protein search engine on the basis of peptide mass matching with redundancy of post-translational modification and proteolysis. The definition of “up-regulated”, “down-regulated” and unique proteins in this study are solely dependent on their existence in SDS-PAGE. When analyzed using Quantity one software (BioRad), the intensity of the bands for up-regulated proteins was more intense in cancerous as compared to normal tissues while the “down-regulated” proteins were those that were more intense in normal as compared to cancerous tissues. However, some of the intense protein bands in SDS-PAGE were found to contain more than one type of protein. Therefore, for the up-regulated and down-regulated protein bands, both the protein bands of the identical molecular weight from normal and cancerous tissues were excised and subjected to LC/MS/MS analysis. The proteins that were detected in both tissues were then quantified by their peptides’ peak areas in selected ion chromatogram analysis. The proteins present in one tissue and not the other are reported as unique proteins.

A total of ninety-five proteins were identified from the protein bands indicated earlier for both the normal and cancerous tissues. However, some of these proteins were of serum origin, due to the embedded blood vessels in the tissues, and these proteins were excluded from the protein list. Furthermore, some of the proteins were represented by more than one band as described by heterogeneity. The heterogeneous proteins were mainly derived from structural, transport and enzyme subunits such as Actin, gamma- enteric smooth muscle, Desmin, Vimetin, Keratin, type I cytoskeletal 10, Cytoskeletal 9, and Triosephosphate isomerase EC 5.3.1.1. Phospholyation, glycosylation and limited proteolytic activities have been considered as major modification of proteins and they therefore affect the mobility of the modified proteins in SDS-PAGE.

The structural proteins were mostly extracted from the cancerous tissues using the S3 buffer. The majority of the structural proteins identified belongs to the cytokeratin family, Williams et al. reported that cytokeratin expressing tumor cells contain cytokeratins 8 and 18, but not
cytokeratin 19 or vimentin. The roles of cytokeratins are commonly known to encompass both structural and signaling capabilities. In the present study, cytokeratin 19 was found in cancerous colon tissues in S3 buffer extracts. The expression of cytokeratin 18 in colon cancerous tissues is consistent with those reported by Leong et al.[25]. In contrast, the expression of cytokeratin 18 was found reduced in malignant tumors of prostate carcinoma compared to benign prostatic hyperplasia[9]. The expression of cytokeratins is sometimes used as an indicator of the behavioral changes of a tissue. For instance, in breast tissue, cytokeratin 8 has been reported to be the major receptor for plasminogen on breast cells[10].

Vimentin is expressed at higher levels in the low-secretant variant. It is present in many cell lines, but normally absent from differentiated cells. Thus, lower vimentin expression in the high secretors may be indicative of a more differentiated phenotype[9]. In our present study, vimentin is a down-regulated protein found in S1 buffer extracts. Williams et al[8] has reported that the absence of vimentin in colon cancer tissue is due to its correlation with cytokeratin 19 or other cytokeratin expressions. However, Birchmeier et al[17] and Seshadri et al[22] reported no unequivocal correlation between a gain of vimentin and poor prognosis with primary tumors.

Hypothetical proteins were extracted in all three extraction buffers from both normal and cancerous colonic tissues. Generally, hypothetical proteins are defined as the proteins that were not described at the protein level, but were predicted from cDNA sequences[23]. As shown in Table 2, a series of hypothetical proteins were identified. Afjelhi-Sadat et al[6] suggested that the hypothetical proteins may serve as marker or protein vaccine candidates. Particularly when the hypothetical protein is found in cancerous tissue exclusively, it can be considered as novel and of pivotal importance. Some of the hypothetical proteins were detected as heterogeneous proteins suggesting the post-translational nature of the proteins.

Peroxiredoxin 2 is a type transport protein and it was extracted in the S1 buffer as a unique protein in normal tissues. Peroxiredoxin 2 is part of the peroxidase family, which are proteins that have been known to connect with cell proliferation, differentiation and apoptosis.

Fibrinogen is a type of channel protein and its role was reported to be supporting the binding of growth factors and promoting the cellular responses of adhesion, proliferation, migration during angiogenesis and tumor cell growth[26]. Fibrinogen was detected in the S2 buffer of cancerous tissues. The presence of fibrinogen in cancer cells was demonstrated to affect the progression of tumor cell growth and metastasis on the basis that fibrinogen alters the ability of breast cancer cells to migrate[56]. In addition, fibrinogen was also found present in lung cancer following the detection of elevated plasma fibrinogen levels in advanced stages of the disease[25] and the localization of fibrinogen in tumor tissue[26,27]. There are also reports of the deposition of fibrinogen on the surfaces of tumor cells and lymphocytes[28,29]. In primary and metastatic tumors[30], the presence of fibrinogen was regarded as an adverse event leading to tumor development. Yamaguchi et al[43] reported that lung cancer was developed through induction of hyperfibrinogenemia.

Transgelin (SM22-alpha) is a cytoskeletal-binding protein that was isolated in S1 buffer as a down-regulated protein. Maguire et al[52] has reported that loss of transgelin expression is an indication of early tumor progression and the authors suggested that transgelin may serve as a diagnostic marker for breast and colon cancer. We found that the expression of transgelin in cancerous tissue is much lower than that of normal tissue. Other cytoskeletal-binding proteins that were detected in S1 buffer extract were Bullous pemphigoid antigen 1 precursor and Skeletal muscle beta-tropomysin.

Some of the enzymes that play important roles in metabolic pathways and are essential for energy production were detected as up-regulated protein in S1 buffer. These enzymes include triosephosphate isomerase and LTRPC6 channel kinase 6. LTRPC6 channel kinase 6 is an essential ion channel and serine/threonine-protein kinase is crucial for magnesium homeostasis. It plays an important role in epithelial magnesium transport and in the active magnesium absorption in the gut and kidney.

Sodium/potassium-transporting ATPase alpha-4 chain was detected as the up-regulated protein in S3 buffer. It is an integral membrane protein that is located in the cell membrane[33]. It catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane.

Carbonate dehydratase is also the up-regulated protein detected in S1 and S2 buffer, it is a zinc-containing enzyme that catalyses the reversible hydration of carbon dioxide, which is significant in the transport of CO₂ from the tissues to the lungs. It was reported that over expression of the zinc enzyme carbonic dehydratase is observed in certain human cancers[34]. Its expression was reported to be elevated in the renal cancer cells as compared to the surrounding normal kidney tissue[35].

DNA-directed RNA polymerase II largest chain is the DNA-RNA binding protein that was detected as unique protein in S1 buffer extract of cancer tissues. It was also reported in human brain tumors[36].

Proteins 14-3-3 are the protein-binding proteins that were isolated in the S1 buffer as unique proteins from colon cancer tissue. Protein 14-3-3 plays a role in the regulation of signal transduction protein pathways implicated in the control of cell proliferation, differentiation and survival[37]. This protein was reported to play multiple roles in maintaining cell survival[38,39]. Friedman et al[46] has reported that protein 14-3-3 in three different isoforms was expressed up to 1.7 fold in the colon tumors as compared to normal colon tissue.

Alpha-1-antitrypsin is an endopeptidase inhibitor protein that was isolated as a unique protein in S1 buffer from normal tissue only. In individuals who lack this inhibitor protein, the protease destroys the membrane system, leaving the colon and rectum vulnerable to colorectal cancer development[40]. The main role of alpha-1-antitrypsin is in defense against elastase damage that occurs in the lung under normal physiology conditions[41]. Alpha-1-antitrypsin was detected in patients with lung cancer[43] and was used as a cancer marker for cervical
cancer\textsuperscript{[44]}. Contrary to our finding, Friedman et al\textsuperscript{[40]} reported the detection of alpha-1-antitrypsin in colon cancer.

ATP (GTP)-binding protein is ATP-binding protein that was detected as down-regulated protein in S2 buffer. It is a mitochondrial membrane protein.

Kinesin is a motor activity protein that was detected as an up-regulated protein in S2 buffer extract. It is a microtubule-associated force-producing protein that may play a role in cytoskeletal transport\textsuperscript{[41]}. This protein was also reported in breast cancer tissue\textsuperscript{[46]}. Kinesin-like protein 2 is an immunogenic breast cancer antigen\textsuperscript{[45]}. In addition, kinesin-like protein 2 was also reported in pancreatic cancer\textsuperscript{[49]}. ACTG1 is another type of motor activity protein that was detected as an up-regulated protein. It is a protein involved in the formation of filaments, which is the major component of the cytoskeleton\textsuperscript{[40]}. Its existence in colorectal cancer was also reported by Vadlamudi and Shin\textsuperscript{[50]}. Alteration of cytoskeletal proteins may have an important role in cancer initiation or progression. Mutations affecting four major cytoskeletal components have now been identified in human neoplastic cells. Chou et al\textsuperscript{[41]} postulated that mutated cytoskeletal genes may be members of a class of oncoproteins, which are fundamentally different from both the nuclear-acting and growth factor/receptor/protein kinase-related types of oncoproteins.

In this study, a number of the differentially expressed proteins extracted from the normal and cancerous colonic tissues were identified. Amongst the proteins identified, some of the proteins have their roles identified in similar or other types of cancers. There are also a series of hypothetical proteins with unknown functions. Some of these proteins have their primary location at the cell membrane, which may serve as potential antigens for drug-targeted therapy or as candidates for vaccines against colon cancer. These proteins are under further investigation in our laboratory.

ACKNOWLEDGMENTS

We would like thank the Ministry of Science, Technology and Innovation in Malaysia for providing the grant to carry out this project. We also want to extend our gratitude to the Ministry of Health in Malaysia for providing tissue specimens for the analysis.

REFERENCES

1 Fearon ER. Molecular biology of gastrointestinal cancers. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 6th ed. Philadelphia: Lippincott, Williams, and Wilkins Press, 2001: 1037-1049
2 Harkins L, Volk AL, Samanta M, Mikolaenko I, Britt WJ, Bland KL, Cobbs CS. Specific localization of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 2002; 360: 1557-1563
3 Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767
4 Alaiya AA, Franzen B, Auer G, Linder S. Cancer proteomics: from identification of novel markers to creation of artificial learning models for tumor classification. Electrophoresis 2000; 21: 1210-1217
5 Stulik J, Herynychová L, Pekertová S, Knízek J, Macela A, Bures J, Jandík P, Langridge JL, Jungblut PR. Proteome study of colorectal carcinogenesis. Electrophoresis 2001; 22: 3019-3025
6 Chong BE, Hamler RL, Lubman DM, Ethier SP, Rosenspire AJ, Miller FR. Differential screening and mass mapping of proteins from premalignant and cancer cell lines using nonporous reversed-phase HPLC coupled with mass spectrometric analysis. Anal Chem 2001; 73: 1219-1227
7 Emmert-Buck MR, Gillespie JW, Pagezelt CP, Ornstein DK, Basrur V, Appella E, Wang QH, Huang J, Hu N, Taylor P, Petricoin EF 3rd. An approach to proteomic analysis of human tumors. Mol Carcinog 2000; 27: 158-165
8 Molloy MP, Herbert RR, Walsh BJ, Tyler ML, Traini M, Sanchez JC, Hochstrasser DF, Williams KL, Gooley AA. Extraction of membrane proteins by differential solubilization for separation using two-dimensional gel electrophoresis. Electrophoresis 1998; 19: 837-844
9 Gam LH, Aishah L. Identification and confirmation of urinary human chorionic gonadotropin using in-gel digestion and HPLC / MS / MS analysis. Jurnal Biosains 2002; 13 (1): 27-34
10 Hjelmeland LM. Solubilization of native membrane proteins. Enzymol 1990; 192: 253-264
11 Rabilloud T. Use of thiourea to increase the solubility of membrane proteins in two-dimensional electrophoresis. Electrophoresis 1998; 19: 758-760
12 Henzel WJ, Billeci TM, Stults JT, Wong SC, Grimley C, Watanabe C. Identifying proteins from two-dimensional gels by molecular mass searching of peptide fragments in protein sequence databases. Proc Natl Acad Sci USA 1993; 90: 5011-5015
13 Figdys D, Gygi SP, Zhang Y, Watts J, Gu M, Aebersold R. Electrophoresis combined with novel mass spectrometry techniques: powerful tools for the analysis of proteins and proteomes. Electrophoresis 1998; 19: 1811-1818
14 Duvert S, Op De Beeck A, Coquereul L, Wychowski C, Cacan R, Dubuisson J. Glycosylation of the hepatitis C virus envelope protein E1 occurs posttranslationally in a mannose/phosphomannose/dolichol-deficient CHO mutant cell line. Glyobiology 2002; 12: 95-101
15 Fountoulakis M, Tsangaris G, Oh JE, Maris A, Lubeck G. Protein profile of the HeLa cell line. J Chromatogr A 2004; 1038: 247-265
16 Williams K, Chubb C, Huberman E, Giometti CS. Analysis of differential protein expression in normal and neoplastic human breast epithelial cell lines. Electrophoresis 1998; 19: 353-343
17 Leong ASY, Cooper K, Leong FJM. Manual of diagnostic antibodies for immunohistology. London: Greenwich Medical Media Pub, 1999: 25-35
18 Hembrough TA, Kralovich KR, Li L, Gonias SL. Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation. Biochem J 1996; 317 (Pt 3): 763-769
19 Ludowyke RI, Warton K, Scurr LL. Inhibition of antigen and calcium ionophore induced secretion from RBL-2H3 cells by phosphatase inhibitors. Cell Biol Int 1998; 22: 855-865
20 Birchmeier C, Birchmeier W, Brand-Saberi B. Epithelial-mesenchymal transitions in cancer progression. Acta Anat (Basel) 1996; 156: 217-226
21 Seshadri R, Raymond WA, Leong AS, Horsfall DJ, McCaul K. Vimentin expression is not associated with poor prognosis in breast cancer. Int J Cancer 1996; 67: 353-356
22 Solomon A, Murphy CL, Weaver K, Weiss DT, Hnric R, Eulitz M, Donnell RL, Sletten K, Westermarck G, Westermark P. Calculifying epithelial odontogenic (Pindborg) tumor-associated amyloid consists of a novel human protein. J Lab Clin Med 2003; 142: 348-355
23 Afjehi-Sadat L, Shin JH, Felizardo M, Lee K, Slavc I, Lubeck G. Detection of hypothetical proteins in 10 individual human tumor cell lines. Biochim Biophys Acta 2005; 1747: 67-80
24 Simpson-Haidaris PJ, Rybarczyk B. Tumors and fibrinogen. The role of fibrinogen as an extracellular matrix protein. Ann N Y Acad Sci 2001; 936: 406-425
25 Edwards RL, Rickles FR, Moritz TE, Henderson WG,
Zacharski LR, Forman WB, Cornell CJ, Forcier RJ, O‘Donnell JF, Headley E. Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 1987; 88: 596-602

26 Ogura T, Hirao F, Tsubura E, Yamamura Y. Autoradiographic study on localization of fibrinogen in rabbit lung cancer. Ganse 1971; 62: 367-372

27 Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kissel W, Kudryk BJ, Rousseau SM, Stump DC. Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. Cancer 1990; 65: 481-485

28 Cardinale M, Uchino R, Chung SI. Interaction of fibrinogen with murine melanoma cells: covariant association with cell membranes and protection against recognition by lymphokine-activated killer cells. Cancer Res 1990; 50: 8010-8016

29 Atagi S, Sone S, Fukuta K, Ogura T. Inhibition by fibrin coagulation of lung cancer cell destruction by human interleukin-2-activated killer cells. Jpn J Cancer Res 1992; 83: 1088-1094

30 Nagy JA, Masse EM, Herberg KT, Meyers MS, Yeo KT, Yeo TK, Stoussat TM, Dvorak HF. Phenotypic analysis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 1995; 55: 360-368

31 Yamaguchi T, Kimura H, Yokota S, Yamamoto Y, Hashimoto T, Nakagawa M, Ito M, Ogura T. Effect of IL-6 elevation in malignant pleural effusion on hyperfibrinogenemia in lung cancer patients. Jpn J Clin Oncol 2000; 30: 53-58

32 Maguire PB, Moran N, Cagney G, Fitzgerald DJ. Application of proteomics to the study of platelet regulatory mechanisms. Trends Cardiovasc Med 2004; 14: 207-220

33 Broude NE, Modyanov NN, Monastyrskaya GS, Sverdlov ED. Advances in Na+,K+-ATPase studies: from protein to gene and back to protein. FEBS Lett 1989; 257: 1-9

34 Whittington DA, Waheed A, Ulmasov B, Shah GN, Grubb JH, Sly WS, Christianson DW. Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells. Proc Natl Acad Sci USA 2001; 98: 9545-9550

35 Türeci O, Sahin U, Vollmar E, Siemer S, Göttert E, Seitz G, Parkkila AK, Shah GN, Grubb JH, Pfreundschuh M, Sly WS. Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carboxylic anhydrase gene that is overexpressed in some renal cell cancers. Proc Natl Acad Sci USA 1998; 95: 7688-7693

36 Cuatico W, Cho JR, Spiegelman S. Particles with RNA of high molecular weight and RNA-directed DNA polymerase in human brain tumors. Proc Natl Acad Sci USA 1973; 70: 2789-2793

37 Fu H, Subramanian RR, Masters SC. 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 2000; 40: 617-647

38 Ichimura T, Isobe T, Okuyama T, Takahashi N, Araki K, Kuwano R, Takahashi Y. Molecular cloning of cDNA coding for brain-specific 14-3-3 protein, a protein kinase-dependent activator of tyrosine and thryptophan hydroxylases. Proc Natl Acad Sci USA 1988; 85: 7084-7088

39 Masters SC, Subramanian RR, Truong A, Yang H, Fujii K, Zhang H, Fu H. Survival-promoting functions of 14-3-3 proteins. Biochem Soc Trans 2002; 30: 360-365

40 Friedman DB, Hill S, Keller JW, Merchant NB, Levy SE, Coffey RJ, Caprioli RM. Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 2004; 4: 793-811

41 Yang P, Cunningham JM, Halling KC, Lesnick TG, Burgart LJ, Wiebert EM, Christensen ER, Lindor NM, Katzmann JA, Thibodeau SN. Higher risk of mismatch repair-deficient colorectal cancer in alpha(1)-antitrypsin deficiency carriers and cigarette smokers. Mol Genet Metab 2000; 71: 639-645

42 Rosenberg S, Barr PJ, Najarian RC, Hallewell RA. Synthesis in yeast of a functional oxidation-resistant mutant of human alpha-antitrypsin. Nature 1984; 312: 77-80

43 Harris CC, Cohen MH,Connor R, Primack A, Saccomanno G, Talamo RC. Serum alpha(1)-antitrypsin in patients with lung cancer or abnormal sputum cytology. Cancer 1976; 38: 1655-1657

44 Govorukhina NI, Keizer-Gunnink A, van der Zee AG, de Jong S, de Brijn HW, Bischoff R. Sample preparation of human serum for the analysis of tumor markers. Comparison of different approaches for albumin and gamma-globulin depletion. J Chromatogr A 2003; 1009: 171-179

45 Bloom GS, Endow SA. Motor proteins 1: kinesins. Protein Profile 1995; 2: 1105-1171

46 Venkatesh LK, Gettemeier T, Chinnadurai G. A nuclear kinesin-like protein interacts with and stimulates the activity of the leucine-rich nuclear export signal of the human immunodeficiency virus type 1 rev protein. J Virol 2003; 77: 7236-7243

47 Scanlan MJ, Gout I, Gordon CM, Williamson B, Stockert E, Gure AO, Jäger D, Chen YT, Mackay A, O’ Hare MJ, Old LJ. Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. Cancer Immunol Immunother 2000; 41: 4-21

48 Fontijn RD, Goud B, Echard A, Jollivet F, van Marle J, Pannekoek H, Horrevoets AJ. The human kinesin-like protein RBEK is under tight cell cycle control and is essential for cytokinesis. Mol Cell Biol 2001; 21: 2944-2955

49 Kabsch W, Vandekerckhove J. Structure and function of actin. Annu Rev Biophys Biomol Struct 1992; 21: 49-76

50 Vadiamudi RK, Shint J. Genomic structure and promoter analysis of the p62 gene encoding a non-proteosomal multiquitin chain binding protein. FEBS Lett 1998; 435: 138-142

51 Chou CC, Davis RC, Fuller ML, Slovin JP, Wong A, Wright J, Kania S, Shaked R, Gatti RA, Salser WA. Gamma-actin: unusual mRNA 3′-untranslated sequence conservation and amino acid substitutions that may be cancer related. Proc Natl Acad Sci USA 1987; 84: 2575-2579